EGFR and non-small cell lung carcinoma: As a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), osimertinib is recommended as the first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) (Maione et al., 2015).